CE Marking (Conformite Europeene) in the European Union has been granted to Abbott Labs to market its rapid, high-throughput PLEX-ID(TM)...
PolyPid Ltd. announced top-line results from the SHIELD I Phase III study of D-PLEX 100 for the prevention of surgical site infections (SSIs) in abdominal surgery
Great Basin Scientific announced that the FDA has granted 510(k) clearance for its Shiga Toxin Direct Test. The Company provides...
Soliris (eculizumab) from AstraZeneca has been approved in Japan for expanded use to include the treatment of generalised myasthenia gravis (gMG) in paediatric patients who are anti-acetylcholine receptor (AChR) antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin (IVIG) therapy or plasmapheresis (PLEX)
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced the first patient has been dosed with imlifidase in the GOOD-IDES-02 trial, a global pivotal phase III trial in anti-glomerular basement membrane (anti-GBM) disease
Hansa Biopharma AB, the pioneer in immunomodulatory enzyme technology for rare IgG-mediated diseases, announces the publication of important data from an investigator-initiated study in anti-GBM in leading nephrology journal Journal of the American Society of Nephrology (JASN).
Myasthenia gravis (MG) is a chronic, fluctuating, antibody-mediated autoimmune disorder directed against the post-synaptic neuromuscular junctions of skeletal muscles, resulting in a wide spectrum of manifestations ranging from mild to potentially fatal
This BSH guideline summarises the recommended initial investigation and first-line management of large B-cell lymphoma (LBCL).
The R-MegaCHOEP trial investigated the use of high-dose chemotherapy and rituximab with subsequent autologous stem cell transplantations compared to conventional immunochemotherapy (R-CHOEP) for high-risk patients up to 60 years.
Actinium Pharmaceuticals, Inc. announced that results from the Phase III SIERRA trial of Iomab-B (apamistamab) were presented in an oral presentation at the 50th Annual European Bone Marrow Transplant Society Meeting (EBMT) held in Glasgow, Scotland on April 14-17